Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE: JNJ) published its earnings report for the fiscal third quarter on Tuesday that topped analysts’ estimates for earnings and revenue. The company attributed its hawkish performance to increased sales for some drugs, and medical devices that it said were highly in demand in the recent quarter.

Johnson & Johnson blows past Wall Street estimates in the third quarter

COVID-19 vaccine developer Johnson & Johnson (NYSE: JNJ) paused an ongoing trial Monday due to an unexplained illness, although it's unknown if the individual in question was given the vaccine or a placebo, J&J CFO Joseph Wolk said on CNBC's "Squawk Box." What Happened: J&J is following all of the established safety protocols, including the pause in the trial, Wolk said.

Johnson & Johnson's CFO On COVID-19 Trial Pause: 'We Are Letting The Science Dictate'

Johnson & Johnson (NYSE:JNJ) released its third-quarter fiscal 2020 results before the opening bell on Oct. 13. The world's biggest maker of consumer health care products posted an earnings and revenue beat and provided a strong outlook for the full year.

Johnson & Johnson's 3rd-Quarter Earnings Surpass Expectations

Johnson & Johnson on Tuesday said it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing the total amount it would pay to $5 billion.

J&J to contribute up to $5 billion to potential opioid settlement

Although Johnson & Johnson (NYSE: JNJ) reported third-quarter earnings and revenue that beat Wall Street's expectations, it also revealed that it would pause its COVID-19 vaccine trial over a participant's ‘unexplained illness'. Its share price fell 1.5% on Tuesday, to $149.55 per share.

Johnson & Johnson Beats Earnings Estimates But Halts Vaccine Trial

JNJ stock is taking a hit on Tuesday after the company announced a pause in its COVID-19 vaccine trial, despite strong Q3 earnings results. The post Johnson & Johnson Earnings: JNJ Stock Ticks Lower as Vaccine Trial Pause Overshadows Q3 Beat appeared first on InvestorPlace.

Johnson & Johnson Earnings: JNJ Stock Ticks Lower as Vaccine Trial Pause Overshadows Q3 Beat

When Johnson & Johnson (NYSE: JNJ) released its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said that it had $2.20 in earnings per share (EPS) and $21.1 billion in revenue.

Are Earnings Enough to Counter COVID-19 Study Setback at Johnson & Johnson?

Pharmaceutical companies will resist pressure from politicians such as U.S. President Donald Trump to speed up the vaccine trial and approval process.

The pause in Johnson & Johnson’s COVID-19 vaccine trial justifies why Big Pharma isn’t eager to rush to market

J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.

J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

Johnson & Johnson reported stronger than expected quarterly profits Tuesday after the drugmaker temporarily halted a crucial late-stage study of its coronavirus vaccine. The New Jersey-based company’s sales jumped 1.7 percent to more than $21 billion from July through September, driving adjusted earnings per share up 3.8 percent to $2.20.

Johnson & Johnson profits jump despite COVID-19 vaccine study snag

Johnson & Johnson paused key final-phase testing of its Covid-19 vaccine candidate, but then beat third-quarter earnings views. JNJ stock fell.

Johnson & Johnson Pauses Covid-19 Vaccine Tests; Raises Earnings Guidance

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 10.55% and 2.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Q3 Earnings and Revenues Beat Estimates

Shares of Johnson & Johnson were down 0.9% in premarket trading on Tuesday though the health care giant beat expectations for the quarter. It had net earnings of $3.5 billion, or $1.33 per share, in the third quarter of 2020, compared with $1.7 billion, or 66 cents per share, in the third quarter of 2019.

J&J's stock falls though third-quarter earnings beat expectations

J&J’s CFO said the pause will allow the data and safety monitoring board to thoroughly investigate the unexplained illness.

Johnson & Johnson's coronavirus vaccine trial paused after 'adverse event' reported 36 hours ago

Shares of Johnson & Johnson (NYSE:JNJ) decreased 1.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 3.77% year over year to $2.20, which beat the estimate of $1.98.

Johnson & Johnson: Q3 Earnings Insights

Johnson & Johnson reported a 1.7% rise in third-quarter sales on Tuesday due to higher demand for its cancer drugs, a day after the company said it had paused its COVID-19 vaccine trials.

Johnson & Johnson sales rise nearly 2% on cancer drug demand

Johnson & Johnson tops expectations on earnings

AstraZeneca

BioNTech SE

CureVac B.V

GlaxoSmithKline

Moderna

Novavax

Pfizer

Sanofi

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Is the Coronavirus Vaccine Market Oversaturated?

J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.

J&J's Coronavirus Vaccine Studies Paused Post Adverse Event

Johnson & Johnson on Tuesday reported third-quarter earnings and revenue that beat Wall Street’s expectations, led by higher sales in its medical-device unit and higher demand for some of its drugs.

Johnson & Johnson beats third-quarter earnings expectations, raises guidance

NEW BRUNSWICK, N.J., Oct. 13, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. "Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical...

Johnson & Johnson Reports 2020 Third-Quarter Results

All of the leading COVID-19 vaccine candidates appear to cause some side effects for some recipients. But there's no reason to worry at this point.

Coronavirus Vaccine Side Effects: 3 Key Things You Need to Know

The pause includes late-stage stage trials for the group’s single dose Covid-19 vaccine.

Johnson & Johnson Halt All Covid-19 Vaccine Trials Over ‘Unexplained Illness’

With many unknowns, it's undetermined how the pause will impact the vaccine candidate's progress.

Report: Johnson & Johnson Coronavirus Vaccine Study Paused Due To Participant's Unexplained Illness

Johnson & Johnson (NYSE: JNJ) stands accused in a lawsuit of deceiving investors regarding performance-based earnings from Auris Health Inc, a medical-robot company it acquired last year for $5.7 billion, Bloomberg reported Monday. What Happened: The lawsuit, filed in the Delaware Court of Chancery, alleges that executives of the New Jersey-based drugmaker “violated the parties’ merger agreement” with the “sole objective” of depriving Auris’ shareholders of billions in earn-out payments.

News for Johnson & Johnson Stock (JNJ)